Target intelligence / Profile preview

Mitochondrial ribosome-associated GTPase 1 (MTG1)

Target
MTG1
Molecular classification
Enzyme (GTPase), Mitochondrial ribosome assembly factor
01

Overview

Mitochondrial ribosome-associated GTPase 1 (MTG1) is a conserved ribosome assembly GTPase critical for mitochondrial protein synthesis. In human mitochondria, MTG1 associates with the large ribosomal subunit in a GTP-dependent manner, where its GTPase activity is stimulated and facilitates incorporation of late-assembly ribosomal proteins. MTG1 acts as a quality control checkpoint, ensuring proper formation of intersubunit bridge during mitoribosome assembly. Depletion of MTG1 impairs mitochondrial translation and leads to defects in assembly/function of respiratory complexes, which in turn disrupts cellular energy production. Besides mitoribosome biogenesis, MTG1 is implicated in cardiac stress responses—helping to preserve respiratory complex activity and protecting against hypertrophy. Pathologically, recurrent MTG1-CYP2E1 fusions serve as molecular markers in certain benign mesenchymal tumors of the female lower genital tract[1][3][2].

Other names
GTPBP7GTP-binding protein 7Mitochondrial GTPase 1mitochondrial ribosome-associated GTPase 1mitochondrial GTPase 1 homolog
02

Biological functions

Mitochondrial translation regulationRibosome assembly (specifically, large subunit)Quality control in mitoribosome assemblyRegulation of respiratory system processesCardiac stress protection
03

Disease associations

Cardiomyopathy and cardiac hypertrophyBenign mesenchymal tumors (MTG1-CYP2E1 fusion in angiomyofibroblastoma and superficial myofibroblastoma of the female lower genital tract)Mitochondrial disorders (due to defects in mitochondrial translation and respiratory complex assembly)
04

Safety considerations

Deficiency causes compromised mitochondrial translation, defective respiratory complex assembly, and early heart lesions/cardiovascular dysfunction in model organismsnull (no drugs targeting MTG1 directly; thus, no therapeutic safety profile known)
05

Biomarkers

MTG1-CYP2E1 fusion transcript (as marker for certain benign mesenchymal tumors)null (for patient selection or efficacy monitoring outside this context)

Beyond the preview

Go deeper on Mitochondrial ribosome-associated GTPase 1 (MTG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial ribosome-associated GTPase 1 (MTG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call